RSV Vaccines for the World 2013 Conference Presentation Highlights Data from ADMA Biologics’ Human and Animal Study Experience

30-10-2013 Business Wire HealthComments (0)

Pharmaceutical

ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases announced today that data from its previous Phase II trial, compassionate use experience and testing in the cotton rat RSV animal model was presented at the 2013 RSV Vaccines for the World Conference (RSVVW). The abstract is titled: “Polyclonal h

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top